Avalo Therapeutics (AVTX) Cash & Equivalents (2014 - 2026)
Avalo Therapeutics' Cash & Equivalents was $85.38 million in Q2 2026, up 101.9% from $42.29 million a year earlier and up 241.7% from the prior quarter.
Avalo Therapeutics (AVTX) Cash & Equivalents (2014 - 2026) Analysis & Trends
At the end of FY2025, Cash & Equivalents at Avalo Therapeutics came in at $15.86 million, down 88.2% from FY2024.
- Cash & Equivalents shows a five-year compound annual growth rate of -3.5% (FY2020 to FY2025).
- In earlier years, Cash & Equivalents was $134.55 million in FY2024, $7.42 million in FY2023 (-43.7%), $13.17 million in FY2022 (-75.9%) and $54.59 million in FY2021 (+188.5%).
- The Q2 2026 figure marks the highest quarterly Cash & Equivalents since Q1 2025.
- Compared with a year earlier, Cash & Equivalents was higher in three of the last seven quarters, with growth averaging 75.6%.
- The best year-over-year quarter for Cash & Equivalents over five years was Q3 2024 (growth of 704.1%); the worst was Q4 2025 (a decline of 88.2%).
- Per Business Quant data, AVTX's Cash & Equivalents in the three quarters before Q2 2026 was $24.99 million (Q1 2026), $15.86 million (Q4 2025) and $26.96 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Avalo Therapeutics | 302.16 Mn | -390.06 Mn | - | 85.38 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 85.38 Mn |
| Mar 31, 2026 | 24.99 Mn |
| Dec 31, 2025 | 15.86 Mn |
| Sep 30, 2025 | 26.96 Mn |
| Jun 30, 2025 | 42.29 Mn |
| Mar 31, 2025 | 125.05 Mn |
| Dec 31, 2024 | 134.55 Mn |
| Sep 30, 2024 | 81.86 Mn |
| Jun 30, 2024 | 93.43 Mn |
| Mar 31, 2024 | 110.18 Mn |
| Dec 31, 2023 | 7.42 Mn |
| Sep 30, 2023 | 10.18 Mn |
| Jun 30, 2023 | 6.31 Mn |
| Mar 31, 2023 | 16.69 Mn |
| Dec 31, 2022 | 13.17 Mn |
| Sep 30, 2022 | 16.94 Mn |
| Jun 30, 2022 | 11.25 Mn |
| Mar 31, 2022 | 38.47 Mn |
| Dec 31, 2021 | 54.59 Mn |
| Sep 30, 2021 | 71.51 Mn |
Avalo Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AVTX&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "AVTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AVTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();